Cryoport
Cryoport's revenue rose 12.4% to $176 million in fiscal 2025. Its operating margin was −20.9%, up from −77.6% a year earlier. Free cash flow was −$25 million. It paid out $10 million in dividends and buybacks. The diluted share count rose 1.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Cryoport does
Cryoport moves and stores biological materials that must stay frozen, such as cell and gene therapies, which are treatments made from a patient's own cells or from altered genes. Its customers are drug and biotech companies, animal health and fertility businesses, universities and government agencies. Cell and gene therapy is its fastest growing market. Cryoport says it supported 760 clinical trials and 20 approved therapies at the end of 2025.
It reports two segments. Life Sciences Services, covers temperature-controlled transport, storage, kit and label production, sample management and freezing of cell therapy starting materials. Its Cryoportal software tracks each shipment. Life Sciences Products, is MVE Biological Solutions, which designs and makes freezers, dewars (insulated flasks for liquid nitrogen) and shipping systems.
In the second quarter of 2025 Cryoport sold its specialty courier business, CRYOPDP, to affiliates of DHL for $133.0 million. That business is shown as a discontinued operation. Cryoport says it competes with other providers of temperature-controlled logistics, storage and cryogenic equipment. It has lost money in the past and has debt and preferred stock outstanding.
Its biggest risks, as it describes them
- Depending on parts from outside makers, where delays or higher costs could hurt its operations.
- Relying on its Cryoportal software and other information systems, which could fail or be attacked.
- Competition, and new products or services that may not gain acceptance.
- Trade policy, tariffs and the many rules that apply to shipping biological materials across borders.
- Past losses, debt, and preferred stock that dilutes common shareholders.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 629 | 523 | 457 | 251 | 411 |
| Debt incl. finance leases | 1 | 1 | 3 | 3 | 2 |
| Net debt (negative means net cash) | −628 | −522 | −454 | −248 | −409 |
| Net debt to EBITDA | −259.6x | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −3.8x | −5.2x | −18.3x | −30.6x | −15.6x |
| Current ratio | 16.3x | 14.8x | 11.7x | 5.3x | 2.2x |
| Quick ratio | 15.9x | 14.1x | 11.2x | 5.0x | 2.1x |
Cash flow
Projections
Project Cryoport's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Cryoport says to expect
- Full year 2026: revenue
Company is providing updated full-year 2026 revenue guidance in the range of $197 million to $199 million.
Insider trades
No officer, director or 10% owner of Cryoport reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 2 of 9 | 4 of 9 |
| Rule of 40 | −52.4% | −28.5% | −1.8% |
| Altman Z'' | 1.56 | −0.69 | 0.96 |
| Accruals ratio | −9.9% | −11.8% | 11.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 3 of 9 | 2 of 9 | 4 of 9 |
Compare
Put Cryoport side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Cryoport | FY25 | 12.4% | −20.9% | −14.2% | −23.4% | — | 4 | |
| Ginkgo Bioworks | FY25 | −25.1% | −185.3% | −105.0% | — | — | — | Compare |
| Maravai LifeSciences | FY25 | −28.3% | −115.9% | −38.1% | −32.0% | — | 2 | Compare |
| PacBio | FY25 | 3.9% | −346.1% | −71.2% | −77.1% | — | 3 | Compare |
| Cytek Biosciences | FY25 | 0.5% | −20.0% | −4.3% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 6 | 12 | 20 | 34 | 79 | 223 | 237 | 169 | 157 | 176 |
| Revenue growth | 49.5% | 103.2% | 64.2% | 72.9% | 131.8% | 182.9% | 6.6% | −28.9% | −7.0% | 12.4% |
| Gross profit | 2 | 6 | 10 | 17 | 36 | 97 | 104 | 75 | 70 | 83 |
| Research and development | 1 | 1 | 2 | 4 | 10 | 17 | 16 | 18 | 18 | 17 |
| Operating income | −9 | −8 | −9 | −18 | −30 | −18 | −32 | −100 | −122 | −37 |
| Net income | −10 | −8 | −10 | −18 | −33 | −276 | −37 | −100 | −115 | 78 |
| Diluted EPS (US$) | −2.05 | −0.34 | −0.34 | −0.55 | −1.94 | −6.18 | −0.93 | −2.21 | −2.49 | 1.40 |
| Diluted shares (millions) | 7 | 23 | 28 | 33 | 39 | 46 | 49 | 49 | 49 | 50 |
| Cash flow | ||||||||||
| Cash from operations | −6 | −4 | −3 | −1 | −15 | 8 | −2 | −1 | −16 | −9 |
| Capital expenditure | 1 | 2 | 3 | 5 | 9 | 24 | 22 | 39 | 17 | 16 |
| Free cash flow | −7 | −5 | −6 | −7 | −24 | −16 | −24 | −40 | −34 | −25 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 38 | 0 | 0 | 10 |
| Acquisitions | 0 | 0 | 0 | 20 | 363 | 6 | 7 | 7 | 0 | 0 |
| Stock-based compensation | 3 | 4 | 6 | 16 | 9 | 15 | 20 | 20 | 17 | 10 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 3 | 15 | 47 | 94 | 93 | 629 | 523 | 457 | 251 | 411 |
| Debt incl. finance leases | — | 0 | 15 | 0 | 5 | 1 | 1 | 3 | 3 | 2 |
| Total assets | 6 | 20 | 57 | 136 | 552 | 1,113 | 1,039 | 958 | 704 | 765 |
| Total liabilities | 3 | 2 | 18 | 10 | 170 | 471 | 483 | 469 | 302 | 262 |
| Shareholders' equity | 3 | 18 | 38 | 126 | 383 | 642 | 556 | 489 | 402 | 503 |
| Margins and ratios | ||||||||||
| Gross margin | 32.1% | 49.9% | 52.2% | 51.1% | 46.2% | 43.4% | 43.8% | 44.7% | 44.4% | 47.1% |
| Operating margin | −148.6% | −66.0% | −44.0% | −52.1% | −38.1% | −8.0% | −13.4% | −59.6% | −77.6% | −20.9% |
| Net margin | −166.9% | −66.1% | −48.7% | −54.0% | −41.5% | −123.8% | −15.7% | −59.0% | −73.2% | 44.4% |
| Free cash flow margin | −126.2% | −44.3% | −31.9% | −19.6% | −30.2% | −7.1% | −10.1% | −23.4% | −21.4% | −14.2% |
| Rule of 40 (growth + FCF margin) | −76.8% | 58.9% | 32.2% | 53.3% | 101.6% | 175.8% | −3.5% | −52.4% | −28.5% | −1.8% |
| Return on capital | — | — | −153.4% | −73.3% | −14.5% | −9.1% | — | — | −101.6% | −23.4% |
| Return on equity | −733.0% | −75.3% | −33.9% | −22.2% | −12.8% | −53.8% | −6.2% | −19.1% | −25.8% | 17.3% |
| Return on assets | −233.0% | −60.6% | −24.9% | −19.1% | −9.5% | −33.1% | −3.5% | −10.0% | −13.8% | 10.7% |
| Net debt to EBITDA | — | — | — | — | — | −259.6x | — | — | — | — |